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ABSTRACT       
Objectives:  To prospectively assess longitudinal lung function in children with sickle cell 
disease (SCD).  
Working hypothesis: Lung function in SCD children deteriorates with increasing age and 
the decline is more marked in younger children who have recently suffered ACS episodes.   
Study design: Two prospective longitudinal studies. 
Patient-subject selection:  Two cohorts of SCD children and age and ethnic matched 
controls were recruited.  Cohort One (47 SCD and 26 controls) had a median age of 8.8 years 
and follow-up of two years and Cohort Two (45 SCD and 26 controls) a median age of 10.2 
years and follow up of ten years.    
Methodology: Forced expiratory volume in one second (FEV1), vital capacity (VC), forced 
expiratory flow between twenty-five and seventy-five % of VC (FEF 25-75), total lung 
capacity (TLC) and residual volume (RV) were measured on two occasions. 
Results: In both groups of SCD children, lung function declined significantly, but in neither 
control group.  ACS episodes were more frequent during the follow up period in Cohort One 
than Cohort Two (p<0.0001). The rate of decline was greater in cohort one than Cohort Two 
for FEV1 (p = 0.008), VC (p = 0.001), FEF25-75 (p = 0.030), TLC (p = 0.004), and RV (p = 
0.043).  In Cohort Two restrictive abnormalities were more common at follow up (p=0.006).   
Conclusions: Lung function deteriorated with increasing age in SCD children and the rate of 
decline was greater in younger children in whom ACS episodes were more common. 
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INTRODUCTION  
 
Sickle cell disease (SCD) is one of the commonest inherited disorders worldwide, affecting 
an estimated 300,000 newborns every year [1].  The majority of children with SCD in 
developed countries can expect to survive to adulthood [2] but may then suffer severe 
respiratory morbidity including chronic hypoxia and pulmonary hypertension [3-9].  Lung 
function abnormalities have been reported even in young SCD children, but there is not a 
consistent picture, cross-sectional studies highlighting restrictive [10, 11] or obstructive [12-
15] abnormalities.  One cross-sectional study, however, suggested the occurrence of 
restrictive abnormalities may increase with increasing age in childhood [11].  More recently, 
longitudinal studies have been undertaken.  In a cohort of 45 children aged between 5 and 18 
years measured at baseline and approximately four years later, a predominantly obstructive 
pattern was reported which increased in prevalence over time; the occurrence of restrictive 
abnormalities also increased, but to a lesser extent [16].  In contrast, retrospective analysis of 
a larger cohort of 413 SCD children aged between eight and eighteen years, who were 
measured on two separate occasions with a variable time to follow-up, demonstrated an 
increased prevalence of restrictive abnormalities with increasing age [17].  There was a 
decline in total lung capacity (TLC) of  2.3% per year [17] and a similar decline in forced 
expiratory volume in one second (FEV1), vital capacity (VC), and forced expiratory flow 
between 25% and 75% of VC (FEF25-75%).  Neither study [16, 17], however, included a 
control group and thus it is not possible to determine whether the decline in lung function 
reported was only seen in SCD patients and hence the magnitude of the effect of SCD.   In 
addition, it is important to assess whether any difference was influenced by increasing age. 
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In adults, acute chest syndrome (ACS) is the commonest cause of death [18, 19] and is 
associated with more severe restrictive disease [20].  In children, ACS episodes have been 
associated with reductions in lung function [21, 22].  The impact of ACS episodes on 
longitudinal changes in lung function, however, has not been investigated [16, 17].  There is 
evidence that asthma may be a risk factor for ACS episodes [21-28].  Hence, in any 
subsequent longitudinal study the impact of asthma also needs to be considered.  
 
The aim of this prospective study was to examine the rate of decline in lung function in 
children with SCD in comparison to age and ethnic matched controls.  Two cohorts were 
studied.  Cohort One were younger children who were followed for approximately two years, 
during an age when ACS episodes are more common [28].  Cohort Two were older and 
followed for approximately ten years.  We included two cohorts as comparison of their 
results would allow us to test our primary hypothesis that the rate of decline in lung function 
would be greater in the younger cohort as it would relate to their higher occurrence of ACS 
episodes.  Furthermore, in Cohort Two, we wished additionally to test the hypothesis that any 
obstructive abnormalities demonstrated at the initial assessment would be replaced by 
restrictive abnormalities at the subsequent assessment.  As asthma may be a risk factor for 
ACS episodes [21-28] we also wished to determine whether asthma and hence baseline 
obstructive lung function abnormalities influenced any change in lung function and whether 
obstructive lung function abnormalities were associated with an increased risk of ACS 
episodes.  Ethnic and age matched controls were recruited for both cohorts to determine 
whether any decline in lung function was only seen in SCD patients.   
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MATERIALS AND METHODS   
 
Study design 
A prospective longitudinal study of children with SCD (homozygous for sickle cell 
hemoglobin (HbSS)) of African-Caribbean or West African descent was undertaken.  Age 
and ethnic matched children without HbSS were recruited as controls; they were siblings of 
the SCD children or recruited from local schools.  Two cohorts were tested, each on two 
occasions.  In Cohort One, changes in lung function over a median follow-up of 
approximately two years and in Cohort Two [26] changes in lung function of children over a 
median follow up of ten years were determined.  Cohort Two were recruited earlier during a 
previous period of research grant funding and both cohorts were followed during a recent 
period of grant funding.  During this period, routine assessment of lung function of SCD 
patients was not undertaken.   Only patients who successfully performed both spirometry and 
body plethysmography were included in the analysis. The study was approved by the King's 
College Hospital Research Ethics Committee and parents gave informed written consent for 
their child to take part. 
 
Lung function assessments 
 
Patients were assessed in the Amanda Smith Pulmonary Function Laboratory at King’s 
College Hospital NHS Foundation Trust.  No subject underwent lung function testing within 
two weeks of an upper respiratory tract infection or within a month of suffering a vaso-
occlusive crisis.  A history was taken of past and current respiratory symptoms and 
medication for respiratory problems. Standing height was measured using a wall-mounted 
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stadiometer (Holtain ltd, Crymych, Dyfed, UK) and weight using electronic weighing scales 
(Seca ltd, Birmingham, UK).   
 
Spirometry was performed and static lung volumes were assessed using whole-body 
plethysmography according to American Thoracic Society/European Thoracic Society 
criteria.  Forced expiratory volume in one second (FEV1), vital capacity (VC), forced 
expiratory flow between twenty-five and seventy-five % of VC (FEF 25-75), total lung 
capacity (TLC) and residual volume (RV) were recorded and the results expressed as the 
percent predicted for height, age and sex [29,30].  The highest forced vital capacity result 
obtained from spirometry and the slow vital capacity from the “plethysmography” manoeuvre 
was reported as VC. Subjects were assessed wearing a nose clip and breathing through a 
mouth piece. Measurements were performed using a pneumotachograph based system (Jaeger 
Masterscreen PFT, Carefusion Ltd, Basingstoke UK).    Spirometry was repeated following 
administration of a bronchodilator (400µg salbutamol via a MDI and spacer) and a positive 
response was defined as an increase in FEV1 of greater than or equal to 12% from baseline.  
Results were expressed as percent predicted for height, age, and sex using the ethnic-specific 
reference equations for spirometry [29] and the European Community for Steel and Coal 
Statement of the European Respiratory Society reference equations for lung volumes and gas 
transfer [31] for patients over eighteen years of age and those of Rosenthal et al for children 
under eighteen [30 ]. The predicted values for total lung capacity were reduced by 12% and 
residual volume by 7% to correct for ethnicity [32].  The lower and upper limits of normal 
were defined as the fifth and ninety-fifth percentiles respectively of the appropriate reference 
range. Patients were diagnosed with a restrictive abnormality if their TLC was less than the 
lower limit of normal (LLN) with a normal FEV1:VC, an obstructive abnormality if their 
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FEV1:VC was less than LLN and a mixed pattern if both TLC and FEV1:VC were less than 
the LLN [32].   
 
Clinical and laboratory characteristics  
The medical records for all SCD children were examined. The occurrence and number of 
ACS episodes during the study period was recorded for each SCD child.  An ACS episode 
was diagnosed if the child had suffered chest pain, dyspnoea and pyrexia together with a new 
pulmonary infiltrate on chest radiograph [19]. SCD children and controls were diagnosed as 
having asthma if they were currently prescribed any anti-asthma medications. Whether the 
child was on a chronic transfusion program or receiving hydroxurea was also noted.    
Hemoglobin concentrations for the SCD children were obtained from routine clinical blood 
samples taken within two months of lung function testing and when the patient was clinically 
stable.  
 
 
Statistical analysis 
 
Differences in lung function results at baseline and follow-up were assessed for statistical 
significance using the Wilcoxon signed-rank test, Fisher’s exact test or Chi-squared test as 
appropriate.   Individual lung function results were reported as the percentage predicted in 
order to normalise results for stature and where appropriate age. Linear mixed model (LMM) 
analysis was then used to analyse trajectories of decline in lung function in the SCD children 
relative to the control groups and to determine the influence of asthma, airways obstruction at 
baseline and the occurrence of ACS during the follow up period.  ACS, airways obstruction 
at baseline and diagnosis of asthma were coded as nominal variables (0 = absent; 1 = 
present).  Models were also fitted to compare the trajectories in the two cohorts.  LMM 
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analysis is an extension of multiple regression, which allows irregularly spaced serial data for 
individuals to be combined in a single linear regression model, providing estimates of both 
individual changes over time and group patterns.   Fixed effects in the models were: ACS 
during the study period, diagnosis of asthma, obstruction at baseline, age at measurement, 
and an intercept term.  Random effect variables comprised age at measurement and an 
intercept term. Models were estimated using restricted maximum likelihood (REML), and 
separate models were fitted for each of the lung function results with all models grand-mean 
centred on age at baseline such that the intercept terms would be interpretable as the mean 
value of the result at baseline, and the slope would represent the annual rate of change. 
Interaction terms were introduced to test the equality of slopes between groups.  Initial 
models included all variables and interactions.  The validity of including the random effects, 
and the selection of an appropriate covariance structure for the residuals was assessed by 
likelihood ratio testing based on the -2 REML log-likelihood difference between the original 
and modified models.  Models were then reduced by the sequential removal of non-
significant terms.  Likelihood ratio tests based on the difference in -2 ML log-likelihood for 
initial and reduced models were used to determine whether a non-significant term should be 
removed [34].  Baseline predictors of future ACS were determined using binary logistic 
regression. 
 
 
 9 
 
RESULTS 
 
Demographics 
 
Cohort One: Forty-seven children with SCD and twenty-six controls were assessed; the two 
groups were of similar age and sex distribution (Table 1). Ten SCD children (21%) had had 
at least one ACS episode during the study.  Nine SCD children and two controls had a 
diagnosis of asthma (p = 0.308). Seven SCD children (14.9%) were prescribed hydroxyurea 
and one (2.1%) was on a chronic transfusion programme within the study period.  The 
majority of the SCD children patients (45) and controls (25) were aged five or above at 
baseline. 
 
Cohort Two: Forty-five children with SCD and twenty-six controls were assessed; the two 
groups were of similar age and sex distribution (Table 1). Twelve SCD children (27%) had 
had at least one ACS episode during the study.  Three SCD children and four controls had a 
diagnosis of asthma (p = 0.227).  Eight SCD children (17.7%) were prescribed hydroxyurea 
and two (4.4%) was on a chronic transfusion programme within the study period. The 
majority of SCD children (43) and controls (24) were aged five or above. 
 
The SCD patients in Cohort One were significantly younger at baseline compared to those in 
Cohort Two (p = 0.007) (Table 1).  The age of the controls in the two cohorts did not differ 
significantly.  The children in Cohort One had a mean of 0.58 (range 0-8.7) ACS 
episodes/year and Cohort Two a mean of 0.09 (range 0-1.3) ACS episodes (p=0.0355).  If 
only the children who had at least one ACS episode were considered in Cohort One this was 
a median of 0.65 (range 0.38-8.7) episodes/year and in Cohort Two 0.11 (range 0.08-1.26) 
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episodes/year (p<0.0001).  The only significant difference in lung function of the two SCD 
cohorts at recruitment was that Cohort One had a higher TLC (p=0.0247).  There were no 
significant differences in the lung function results of the two control groups at recruitment.   
 
Lung function changes with increasing age 
 
 
In both cohorts, lung function declined significantly in the SCD children, but in neither 
control group (Tables 2 and 3). Lung function results as z-scores  are presented in tables E1 
and E2 in the online supplement. 
 
Lung function abnormalities at baseline and follow-up 
 
At baseline, sixteen SCD children in Cohort One (34%) had an obstructive pattern, and one 
(2%) a restrictive defect; no child had a mixed defect.  At follow-up, the number of subjects 
with an obstructive defect had declined to five (10.6%, p = 0.021), the number with 
restrictive defects increased to eight (17%, p = 0.034) and two patients had a mixed pattern 
(4.3%, p = 0.495).  A positive response to a bronchodilator was seen in four SCD children 
(16.7%) at baseline and three (12.5%) at follow-up (p= 1.000).  In Cohort Two, at baseline, 
eleven SCD children (24%) had an obstructive pattern and five (11%) a restrictive defect; no 
child had a mixed defect. At follow-up, five subjects had an obstructive defect (11.1%, p = 
0.167), the number with restrictive defects had increased to twenty (44%, p = 0.0008) and 
three patients had a mixed pattern (6.7%, p = 0.242). A positive bronchodilator response was 
seen in seven subjects (15.6%) at baseline and one subject (2.2%) at follow-up (p=0.059).   
At baseline, the proportion of SCD children with obstructive and restrictive defects was 
similar in both cohorts (p = 0.364, p = 0.107 respectively). At follow-up, Cohort Two 
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compared to Cohort One had a greater proportion of SCD children with a restrictive defect (p 
= 0.006), but a similar number with an obstructive defect (p = 0.792). In Cohort Two, patients 
with an obstructive defect at baseline were more likely to have a restrictive abnormality at 
follow-up (p=0.0289).   
 
In neither control group was there a significant change in the patterns of lung function over 
the follow up period.  Amongst the controls in Cohort One, three had an obstructive 
abnormality and none a restrictive abnormality at baseline and follow up.  Amongst the 
controls in Cohort Two, two had an obstructive lung function abnormality and none a 
restrictive abnormality at baseline and follow up.   
 
Lung function abnormalities and ACS 
 
In both cohorts, there were significant correlations in the SCD children between obstructive 
defects at baseline and ACS episodes (p=0.0003 for Cohort One, p=0.028 for Cohort Two).  
In Cohorts One and Two, in the SCD children the presence of obstructive defects at baseline 
was predictive of an ACS episode during the study: odds ratio (OR) 13.9 (95%CI 2.5 – 77.0), 
p= 0.003 and 5.4 (95%CI 1.2 – 23.7), p= 0.026 respectively.  In Cohort One there was no 
independent association in the SCD children between asthma and a subsequent ACS episode: 
OR 6.1 (95% CI -0.5 – 12.8, p = 0.070).  ACS episodes occurred more frequently in the SCD 
children in Cohort One than Cohort Two (one episode per 1.93 patient/years versus one 
episode per 12.6 patient/years (p<0.0001).   
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Lung function decline in SCD children and controls 
 
In Cohort One, a significant decline was observed in the SCD children relative to the controls 
in FEV1 (p=0.027), VC (p<0.0001), FEF25-75 (p=0.042), TLC (p<0.0001) and RV (p=0.001) 
(see supplement Table E3) .  In Cohort Two, a significant decline was observed relative to the 
controls in FEV1 (p=0.001), VC (p=0.004), FEF25-75 (p=0.016) and TLC (p=0.002) (see 
supplement Table E4) .  The rate of decline was significantly greater in Cohort One than 
Cohort Two for FEV1 (p = 0.008), VC (p = 0.001), FEF25-75 (p = 0.030), TLC (p = 0.004), 
and RV (p = 0.043) (see supplement Table E5).   
 
Predictors of lung function decline in SCD children 
In Cohort One, obstructive defects at baseline were linked to a lower intercept (baseline 
value) for FEV1 (p = 0.027) and FEV1:VC ( p < 0.0001). The occurrence of ACS episodes 
was associated with a more rapid decline (i.e. greater negative slope) for FEV1 (p=0.005), VC 
(p=0.022), FEF25-75 (p=0.003) and TLC (p=0.004).  In Cohort Two, obstructive defects at 
baseline were linked to a lower intercept (baseline value) for FEV1 (p = 0.011), FEV1:VC (p 
< 0.0001), and FEF25-75 (p = 0.013), whilst ACS episodes were  associated with a  more rapid 
decline (i.e.: greater negative slope) for VC (p = 0.031) and TLC (p = 0.026), and an increase 
(i.e. more positive slope) in  FEV1:VC (p = 0.049) (see supplement Tables E6 and E7). No 
significant effects of hydroxyurea use or chronic transfusion were seen during exploratory 
analysis when those factors were included as covariates in the models (see supplement Tables 
E6 and E7), nor did their inclusion as non-significant terms improve the model fit as assessed 
by likelihood ratio testing.  
 13 
 
DISCUSSION  
 
We have demonstrated that lung function declines in children with SCD compared to similar 
aged, ethnic matched controls.  The average annual rate of decline for all lung volumes was 
significantly greater in Cohort One compared to Cohort Two, which suggests the most rapid 
period of deterioration takes place during early childhood.  This deterioration represents a 
progression towards a restrictive pattern of lung function with increasing age.  We 
demonstrated that ACS episodes were the only independent predictor of a greater decline in 
lung volumes. ACS episodes occurred more frequently per unit follow up period in Cohort 
One who were followed up for two years compared to Cohort Two who were followed up for 
ten years.  Thus ACS episodes might explain the greater rate of decline in lung function in 
Cohort One and hence our results emphasize the need for more effective methods of 
preventing ACS episodes, such as an increased use of hydroxyurea.   
 
The rate of decline in lung volumes observed in the SCD children in Cohort One, that is the 
younger children, was similar to that demonstrated by Maclean et al [17], who observed an 
annual reduction in TLC of around 2.3% per year, with proportionate reductions in FEV1, 
VC, and FEF25-75.  Unlike Maclean et al, however, we did not detect a decline in RV:TLC in 
the SCD children. This difference may be explained by Maclean not expressing RV:TLC as a 
percentage of the predicted value and therefore not accounting for age-related changes in 
RV:TLC [35].  
 
The prevalence of obstructive lung disease in the SCD children at baseline was similar in 
both cohorts (34 and 24% respectively) and to that observed by Koumbourlis et al (22%) 
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[16], but higher than that reported by MacLean et al. The latter difference may be due to 
MacLean’s use of a fixed cutoff for FEV1:VC to define an obstructive defect, whereas this 
study used the lower limit of normal based on a reference range.   After criticism from 
Koumbourlis [36], Maclean and coworkers subsequently reanalyzed their data using the 
lower limit of normal to define abnormality and found that more patients had a diagnosis of 
obstruction than reported in the original study [37].  The proportion of patients with 
restrictive disease at baseline was lower in the SCD children Cohort One to that observed by 
Koumbourlis (22%), but similar in Cohort Two. Cohort One was, however, younger than the 
cohort of Koumbourlis (8.8 versus 10.6 years), whereas Cohort Two was of a similar age 
(10.2 years) [16]. The prevalence of restrictive defects at baseline was higher at follow-up in 
Cohort Two than in Maclean’s cohort when assessed at age seventeen (18.7%) [17]. That 
difference may be explained by Maclean using a fixed cutoff of <70% predicted for TLC to 
define restriction, which may have resulted in mis-diagnosis.  
 
Although ACS episodes were linked to a faster progression of restrictive disease, whether the 
prompt treatment of airflow obstruction in SCD might help prevent the development of 
restrictive lung disease in later life is unknown.  The incidence of obstructive defects at 
baseline was higher than that of a diagnosis of asthma, which suggests other mechanisms 
may be responsible for obstructive defects in SCD.  Indeed, we have recently demonstrated 
an association between pulmonary vascular engorgement and obstructive lung function in 
both adults [38] and children with SCD [15]. Hence, any preventative strategy needs to 
consider this abnormality in SCD children.   
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This study has strengths and some limitations.  The novelty of our data is that we have 
longitudinally assessed SCD patients and ethnic and age matched controls.  .To the best of 
our knowledge, this is the first longitudinal study to include matched controls evaluated in 
parallel with SCD children.  We also monitored patients prospectively and used a consistent 
definition to document the occurrence of ACS episodes during the study period.  The 
inclusion of two SCD groups with two and ten-year follow-up periods respectively allowed 
both the short and long term changes in lung function in childhood to be evaluated.   We used 
ethnic-specific reference equations for spirometric results, but the static lung volume results 
were related to two reference ranges derived from Caucasian children and adults with a fixed 
correction factor to account for ethnicity as no ethnic-specific reference values are currently 
available. This adjustment is, however, imprecise and may have resulted in some inaccuracy.  
The change in lung function was, therefore, referenced to an ethnic-matched control group in 
each cohort so that interpretation of within-cohort changes in the SCD children was valid.  
Indeed, the pattern of change in static lung volumes was similar to that in spirometric 
measurements.  We did not exclude patients who were treated with hydroxyurea or chronic 
transfusions, as this would have biased the study population in favor of SCD children with 
less severe disease.  Inclusion of those treatments into the analysis did not result in any 
significant differences in the results, but the number of children receiving such treatments 
was small and hence it would be inappropriate to draw conclusions from those results.      
 
In conclusion, lung function in children with sickle cell disease declines and the rate of 
decline was greater in young children in whom ACS episodes were more common.  Our 
results suggest treatment strategies to prevent ACS episodes need to be started in young SCD 
children if they are to be most effective in preventing the decline in lung function.  
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Table 1: Demographics by SCD status 
Data are demonstrated as n (%) or median (range) 
 
  SCD Controls p 
Cohort One   
 
N 47 26 
 
Males (%) 21 (45%) 7 (27%) 0.352 
Age at baseline (years) 8.8 (3.0-13.1) 10.2 (4.0-14.6) 0.072 
Time to follow-up (years) 2.0 (0.9-3.5) 1.7 (1.5-2.51) 0.518 
Hb (g/dL) 8.2 (4.6-11.9)     
Cohort Two   
 
N 45 24 
 
Males (%) 19 (42.2%) 8 (33.3%) 0.81 
Age at baseline (years) 10.2 (4.3-16.0) 8.5 (4.0-17.8) 0.24 
Time to follow-up (years) 9.9 (6.0-13.5) 11.4 (7.0-13.4) 0.063 
Hb (g/dL) 8.2 (5.7-12.8)     
 
 
 
 
 
 
 
 
 
Table 2: Lung function in Cohort One by follow up status.  
Data are presented as expressed as percent predicted and median (range) and.  
 
 
SCD children 
Baseline  Follow-up  p 
FEV1 91.6 (70.5-117.5) 88.7 (55.5-122.6) 0.0297 
VC 97.2 (67.3-140.8) 91.8 (59.4-123.5) 0.0002 
FEF25-75 91.8 (40.4-189.6) 82.4 (29.7-146.7) 0.0001 
FEV1/VC 94.7 (71.8-109.8) 95 (72.2-111.8) 0.2318 
TLC 97.2 (72.1-127.1) 89.7 (68.5-121.4) <0.0001
RV 107.4 (40.6-212.0) 95.5 (42.2-160.0) 0.0032 
RV/TLC 128.2 (68.2-218.5) 120.1 (52.5-182.8) 0.469 
Controls 
     
FEV1 94.2 (73.4-129.3) 100.6 (76.7-131.0) 0.2427 
VC 98.9 (79.6 – 129.2) 99.2 (80.5 – 136.6) 0.0988 
FEF25-75 96.3 (37.5-160.1) 96.7 (45.5-158.6) 0.3219 
FEV1/VC 98.5 82.3-108.8) 97.3 (76.9-112.8) 0.5938 
TLC 94.8 (80.8-115.5) 98.2 (78.2-115.5) 0.8789 
RV 101.4 (66.6-172.2) 102.5 (57.2-161.6) 0.3539 
RV/TLC 104.7 (72.1-137.1) 100.2 (62.2-160.8)  0.4164  
 
 
 
 
 
 
 
Table 3: Lung function in Cohort Two by follow up status.   
 
Data are expressed as percent predicted and presented as median (range).  
 
 
SCD children 
Baseline  Follow-up p 
FEV1 90.7 (64.0-117.2) 81.2 (66.4-106.7) 0.0002 
VC 97.6 (62.6-116.7) 85.4 (68.7-109.6) 0.0003 
FEF25-75 91.8 (45.9-144.9) 74.5 (28.9-122.7) <0.0001
FEV1/VC 96.2 (69.7-109.4) 95.4 (64.4-108.1) 0.7648 
TLC 92.5 (67.6-127.1) 81.6 (61.0-108.3) <0.0001
RV 101.2 (37.7-212.0) 88.9 (54.8-149.2) 0.0300 
RV/TLC 121.2 (73.4-194.3) 113.2 (67.5-221.5) 0.0692 
Controls 
     
FEV1 99.8 (73.8-128.8) 100.3 (76.8-148.7) 0.0946 
VC 103.1 (71.3-131.2) 102.7 (86.2-124.6) 0.1747 
FEF25-75 92.7 (55.3-168.3) 102.3 (54.7-163.0) 0.0891 
FEV1/VC 98.8 (81.1-112.2) 96.3 (84.9-116.6) 0.7425 
TLC 98.3 (78.5-111.8) 94.0 (84.2-121.8) 0.9421 
RV 95.7 (50.5-165.1) 91.1 (33.0-154.3) 0.9431 
RV/TLC 110.2 (63.2-175.7)  94.6 (45.0-158.7)  0.0742  
  
 
 
 
 
 
